Skip to Content

Gheath Alatrash

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002 University of North Texas Health Science Center, Fort Worth, TX, DO, Highest Honors, Osteopathic Medicine
2002 University of North Texas Health Science Center, Fort Worth, TX, PHD, Biomedical Sciences
1995 Abilene Christian University, Abilene, TX, BS, Magna Cum Laude, Biology

Postgraduate Training

2005-2008 Clinical Fellowship, Medical Oncology/Hematology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
2002-2005 Clinical Residency, Internal Medicine, Scholar Pathway (Clinician), The Cleveland Clinic Foundation, Cleveland, OH

Experience/Service

Academic Appointments

Instructor, Department of Stem Cell Transplantation - Research, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2008-6/2009
Chief Fellow, Medical Oncology/Hematology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2007-2008

Selected Publications

Peer-Reviewed Original Research Articles
1. Alatrash G, Majhail N, Pile J. Rhabdomyolysis following the ingestion of 'Foxy'. Mayo Clinical Proceedings 81(4):550-1, 2006. PMID: 16610577.
2. Alatrash G, Hutson TE, Nemec C, Mekhail T, Richmond A, Molto L, Elson P, Tannenbaum C, Finke J, Olencki T, Bukowski RM. Clinical and immunologic effects of subcutaneously administered IL-12 and IFN-a2b: Phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. Journal of Clinical Oncology 22(14):2891-900, 2004. PMID: 15254058.
3. Alatrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH. IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochem Biophys Res Commun 292(1):184-9, 3/2002. PMID: 11890690.
4. Datta A, Kitson RP, Xue Y, Alatrash G, Mazar AP, Jones TR, Goldfarb RH. Combined chemo/anti-angiogenic cancer therapy against Lewis lung carcinoma (3LL) pulmonary metastases. In Vivo 16(6):451-7, 2002. PMID: 12494889.
5. Alatrash G, Kitson RP, Xue Y, Mazar AP, Kim MH, Goldfarb RH. uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Res 21(3B):1697-704, 5/2001. PMID: 11497249.
6. Alatrash G, Kitson RP, Xue Y, Goldfarb RH. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion. In Vivo 14(5):565-70, 9/2000. PMID: 11125540.
7. Goldfarb RH, Koelemij R, Muirhead KA, Ohlsson-Wilhelm BM, Gray BD, Kuppen PJ, Basse PH, Alatrash G, Kitson RP. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. In Vivo 14(1):101-4, 1/2000. PMID: 10757065.
8. Alatrash G, Keating MJ, O'Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Kantarjian HM, Lerner S, Wierda WG. Circulating CD52 and CD20 levels predict for progression and survival in patients with CLL treated with Fludarabine (F), Cyclophosphamide (C), and Rituximab (FCR). Submitted.

Last updated: 8/28/2009